Omnicell's Q2 EPS exceeded estimates, receiving mixed analyst ratings and price target increases.
Omnicell, a US-based healthcare firm, has received mixed ratings from analysts, including Bank of America's price target increase from $34.00 to $44.00 and a "buy" rating, and Barclays' upgrade from underweight to equal weight with a $39.00 price target. Omnicell's Q2 EPS of $0.51 surpassed the consensus estimate of $0.14, and the company offers medication management solutions and adherence tools for healthcare systems and pharmacies.
August 06, 2024
5 Articles